Imeik Technology DevelopmentLtd Valuation
Is 300896 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Earnings gegen Gleichaltrige
Price-To-Earnings gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of 300896 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: 300896 (CN¥325.31) wird unter unserer Schätzung des Fair Value (CN¥433.24) gehandelt.
Deutlich unter dem Marktwert: 300896 wird um mehr als 20 % unter dem Marktwert gehandelt.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 300896?
Other financial metrics that can be useful for relative valuation.
| What is 300896's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | CN¥68.88b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 22.7x |
| Enterprise Value/EBITDA | 31.3x |
| PEG Ratio | 1.5x |
Price to Earnings Ratio vs Peers
How does 300896's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 35.2x | ||
603392 Beijing Wantai Biological Pharmacy Enterprise | 65.3x | 71.1% | CN¥81.5b |
300122 Chongqing Zhifei Biological Products | 12.8x | 19.0% | CN¥108.6b |
002252 Shanghai RAAS Blood Products | 22.7x | 14.9% | CN¥46.9b |
600161 Beijing Tiantan Biological Products | 40.1x | 17.9% | CN¥44.5b |
300896 Imeik Technology DevelopmentLtd | 37.1x | 25.0% | CN¥68.9b |
Price-To-Earnings gegen Gleichaltrige: 300896 ist auf der Grundlage des Price-To-Earnings Verhältnisses (41.4x) im Vergleich zum Durchschnitt der Vergleichsgruppe (27.2x) teuer.
Price to Earnings Ratio vs Industry
How does 300896's PE Ratio compare vs other companies in the CN Biotechs Industry?
Price-To-Earnings gegen Industrie: 300896 ist aufgrund seines Price-To-Earnings Verhältnisses (39.9x) im Vergleich zum CN Biotechs Branchendurchschnitt (40.5x) ein guter Wert.
Price to Earnings Ratio vs Fair Ratio
What is 300896's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 37.1x |
| Fair PE Ratio | 34.7x |
PM vs. Fair Ratio: 300896 ist teuer auf der Grundlage des Verhältnisses Price-To-Earnings (41.4x) im Vergleich zum geschätzten fairen Verhältnis Price-To-Earnings (35.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | CN¥320.06 | CN¥454.45 +42.0% | 19.5% | CN¥669.30 | CN¥377.00 | n/a | 11 |
| Mar ’25 | CN¥321.22 | CN¥456.90 +42.2% | 24.8% | CN¥669.30 | CN¥310.00 | n/a | 11 |
| Feb ’25 | CN¥282.38 | CN¥473.44 +67.7% | 25.1% | CN¥669.30 | CN¥310.00 | n/a | 11 |
| Jan ’25 | CN¥294.33 | CN¥521.60 +77.2% | 20.1% | CN¥669.30 | CN¥310.00 | n/a | 11 |
| Dec ’24 | CN¥298.00 | CN¥553.80 +85.8% | 10.9% | CN¥669.30 | CN¥444.00 | n/a | 10 |
| Nov ’24 | CN¥323.60 | CN¥568.09 +75.6% | 11.1% | CN¥669.30 | CN¥444.00 | n/a | 11 |
| Oct ’24 | CN¥390.27 | CN¥631.54 +61.8% | 6.1% | CN¥670.00 | CN¥557.00 | n/a | 11 |
| Sep ’24 | CN¥439.00 | CN¥631.54 +43.9% | 6.1% | CN¥670.00 | CN¥557.00 | n/a | 11 |
| Aug ’24 | CN¥456.68 | CN¥652.18 +42.8% | 7.8% | CN¥763.00 | CN¥557.00 | n/a | 11 |
| Jul ’24 | CN¥444.95 | CN¥674.22 +51.5% | 5.0% | CN¥763.00 | CN¥630.00 | n/a | 9 |
| Jun ’24 | CN¥455.60 | CN¥684.75 +50.3% | 6.0% | CN¥763.00 | CN¥630.00 | n/a | 8 |
| May ’24 | CN¥543.97 | CN¥696.17 +28.0% | 7.3% | CN¥787.50 | CN¥630.00 | n/a | 9 |
| Apr ’24 | CN¥558.75 | CN¥694.83 +24.4% | 7.5% | CN¥787.50 | CN¥622.00 | CN¥349.92 | 9 |
| Mar ’24 | CN¥590.00 | CN¥665.43 +12.8% | 11.8% | CN¥788.70 | CN¥605.15 | CN¥321.22 | 7 |
| Feb ’24 | CN¥604.00 | CN¥665.43 +10.2% | 11.8% | CN¥788.70 | CN¥605.15 | CN¥282.38 | 7 |
| Jan ’24 | CN¥566.35 | CN¥659.25 +16.4% | 9.9% | CN¥787.50 | CN¥605.15 | CN¥294.33 | 8 |
| Dec ’23 | CN¥497.25 | CN¥659.25 +32.6% | 9.9% | CN¥787.50 | CN¥605.15 | CN¥298.00 | 8 |
| Nov ’23 | CN¥455.00 | CN¥656.58 +44.3% | 10.7% | CN¥787.50 | CN¥557.18 | CN¥323.60 | 9 |
| Oct ’23 | CN¥490.32 | CN¥666.25 +35.9% | 10.7% | CN¥787.50 | CN¥557.18 | CN¥390.27 | 8 |
| Sep ’23 | CN¥540.06 | CN¥668.12 +23.7% | 11.2% | CN¥787.50 | CN¥557.18 | CN¥439.00 | 7 |
| Aug ’23 | CN¥600.50 | CN¥664.35 +10.6% | 10.6% | CN¥787.50 | CN¥557.18 | CN¥456.68 | 8 |
| Jul ’23 | CN¥590.96 | CN¥654.22 +10.7% | 13.0% | CN¥787.50 | CN¥557.18 | CN¥444.95 | 4 |
| Jun ’23 | CN¥529.00 | CN¥654.22 +23.7% | 13.0% | CN¥787.50 | CN¥557.18 | CN¥455.60 | 4 |
| May ’23 | CN¥517.50 | CN¥654.22 +26.4% | 13.0% | CN¥787.50 | CN¥557.18 | CN¥543.97 | 4 |
| Apr ’23 | CN¥490.88 | CN¥684.29 +39.4% | 11.0% | CN¥787.50 | CN¥611.29 | CN¥558.75 | 3 |
Analysten-Prognose: Das Kursziel liegt um mehr als 20% über dem aktuellen Aktienkurs, aber die Analysten liegen nicht in einem statistisch sicheren Bereich der Übereinstimmung.